• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanobiotix inks $47m financing to support nanomedicine development

July 30, 2018 By Sarah Faulkner

Nanobiotix nanoparticleNanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies.

The Paris, France-based company said it landed a five-year loan to borrow up to €40 million ($46.7 million) contingent upon a set of performance milestones.

Nanobiotix plans to use the funds to bring its NBTXR3 product into clinical trials for people with head and neck cancer. The drug is designed to destroy tumors and trigger the body’s immune system when activated by radiotherapy.

In December last year, Nanobiotix won FDA approval to start a clinical trial of NBTXR3 combined with anti-PD1 antibodies in lung and head and neck cancer patients. The company also has ongoing studies in patients with liver cancers, locally advanced or unresectable rectal cancer and prostate adenocarcinoma.

“Cancer is the second-highest cause of death in the EU and with Europe’s aging population, fighting cancer will undoubtedly remain a priority in the years to come,” EU commissioner Vytenis Andriukaitis said in prepared remarks. “We need to have innovative and dedicated research to always be in search of new treatments. Nanoparticle-based cancer treatment research funding is one example of how serious we are in fighting cancer, with the significant support from the EIB to finance research and innovation.”

“We are pleased to have the European Investment Bank on board as a new financing partner. This loan will significantly enhance our financial visibility without diluting our shareholders in the medium term. This new partnership is another value recognition of the product the company wants to bring to market to help millions of cancer patients,” Nanobiotix CFO Philippe Mauberna added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: nanobiotix

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS